HALO - Halozyme Therapeutics, Inc.
| Previous Close | 17.91 |
| Open | 17.18 |
| Bid | 16.10 x 1000 |
| Ask | 19.06 x 900 |
| Day's Range | 16.87 - 17.91 |
| 52 Week Range | 12.71 - 22.06 |
| Volume | 1,032,453 |
| Avg. Volume | 1,887,732 |
| Market Cap | 2.416B |
| Beta (5Y Monthly) | 1.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings Date | May 04, 2020 - May 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.20 |
- Zacks
Halozyme Therapeutics (HALO) Down 20.1% Since Last Earnings Report: Can It Rebound?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Is Halozyme Therapeutics (HALO) Stock a Solid Choice Right Now?
Halozyme Therapeutics (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- Thomson Reuters StreetEvents
Edited Transcript of HALO earnings conference call or presentation 24-Feb-20 9:30pm GMT
Q4 2019 Halozyme Therapeutics Inc Earnings Call
- Zacks
Surging Earnings Estimates Signal Good News for Halozyme (HALO)
Halozyme (HALO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
- Simply Wall St.
Halozyme Therapeutics, Inc. Just Released Its Annual Results And Analysts Are Updating Their Estimates
Halozyme Therapeutics, Inc. (NASDAQ:HALO) came out with its annual results last week, and we wanted to see how the...
- PR Newswire
Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4 at 11:20 a.m. ET / 8:20 a.m. PT in Boston. Dr. Helen Torley, president and chief executive officer, will provide a corporate overview.
- Zacks
Halozyme (HALO) Q4 Earnings and Revenues Miss Estimates
Halozyme (HALO) reports wider-than-expected loss and misses revenue estimates in fourth-quarter 2019. Shares down.
- PR Newswire
Halozyme Announces FDA Has Accepted Biologics License Application For Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Enhanze® Technology
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration has accepted a Biologics License Application (BLA) from Genentech, a member of the Roche Group, for the fixed-dose combination of pertuzumab (Perjeta®) and trastuzumab (Herceptin®) for subcutaneous administration using Halozyme's ENHANZE® drug delivery technology in combination with intravenous (IV) chemotherapy for the treatment of eligible patients with HER2-positive breast cancer.
- Zacks
Halozyme Therapeutics (HALO) Reports Q4 Loss, Lags Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -33.33% and -2.82%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Halozyme Reports Fourth Quarter and Full Year 2019 Results
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on its recent corporate activities and outlook.
- PR Newswire
Halozyme Announces CFO Transition
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine D. Sun has been appointed senior vice president and chief financial officer, effective March 2, 2020. Ms. Sun will succeed Laurie Stelzer, who has resigned to pursue another opportunity.
- PR Newswire
Halozyme To Host Fourth Quarter And Full Year 2019 Financial Results Webcast And Conference Call
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter 2019 on Monday, February 24 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the fourth quarter and year ended December 31, 2019 following the close of trading.
- Simply Wall St.
Is Halozyme Therapeutics (NASDAQ:HALO) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- PR Newswire
Halozyme Provides 2020 Business Update And Financial Guidance
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update on its outlook for 2020, including financial guidance.
- PR Newswire
Halozyme Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16 at 8:30 a.m. PT / 11:30 a.m. ET. Dr. Helen Torley, president and chief executive officer, will provide a corporate overview.
- Zacks
Why Is Halozyme Therapeutics (HALO) Up 6.1% Since Last Earnings Report?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire
Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that new data from the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, will be presented today at the 2019 San Antonio Breast Cancer Symposium (SABCS).
- Insider Monkey
Hedge Funds Are Betting On Halozyme Therapeutics, Inc. (HALO)
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
- Thomson Reuters StreetEvents
Edited Transcript of HALO earnings conference call or presentation 12-Nov-19 9:30pm GMT
Q3 2019 Halozyme Therapeutics Inc Earnings Call
- Zacks
Halozyme Therapeutics (HALO) Looks Good: Stock Adds 5.4% in Session
Halozyme Therapeutics (HALO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- PR Newswire
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024
SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced the pricing of $400.0 million aggregate principal amount of its convertible senior notes due 2024 (the "Convertible Notes"). The Convertible Notes are being offered in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company granted an option to the initial purchasers to purchase up to an additional $60.0 million aggregate principal amount of Convertible Notes.
- Zacks
Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3
Halozyme (HALO) reports lower-than-expected earnings and revenues in third-quarter 2019. It lowers the sales outlook for 2019 and raises the same for operating expenses.
- Zacks
Halozyme Therapeutics (HALO) Reports Q3 Loss, Misses Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -41.67% and -21.40%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Bernadette Connaughton Appointed to Syneos Health Board of Directors
MORRISVILLE, N.C., Nov. 12, 2019 -- Syneos Health® (Nasdaq:SYNH), a leading biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and a.
- PR Newswire
Halozyme Therapeutics, Inc. Announces Proposed Offering of $400 Million of Convertible Senior Notes due 2024
SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced that it intends to offer, subject to market conditions and other factors, $400 million aggregate principal amount of convertible senior notes due 2024 (the "Convertible Notes"). The Convertible Notes are to be offered and sold to "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company also expects to grant a 30-day option to the initial purchasers to purchase up to an additional $60 million aggregate principal amount of Convertible Notes.
